Navigation Links
Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
Date:4/23/2009

cacy of 28- and 48-week lead-in regimens of boceprevir (800 mg TID) in combination with PEGINTRON (1.5 mcg/kg/week) and REBETOL (600-1400 mg/day) compared to a control of PEGINTRON and REBETOL alone for 48 weeks in treatment-naive adult patients with chronic HCV genotype 1. The study enrolled a total of 1,099 patients, including 158 African-American/Black patients.

The HCV RESPOND-2 study evaluates 36- and 48-week lead-in regimens of boceprevir in combination with PEGINTRON and REBETOL at the same doses as described above compared to a control of PEGINTRON and REBETOL alone for 48 weeks in adult patients with chronic HCV genotype 1 who failed prior treatment (relapsers and nonresponders) with peginterferon and ribavirin combination therapy. The study enrolled a total of 404 patients.

In both registration studies, RVR criteria at 4 weeks of boceprevir treatment (treatment week 8) is used to determine which boceprevir patients can stop all treatment at 28 weeks (HCV SPRINT-2) or 36 weeks (HCV RESPOND-2).

For more information about ongoing studies, please visit www.clinicaltrials.gov, search term boceprevir or SCH 900518.

About Hepatitis C

Hepatitis C is a serious and potentially life-threatening disease. It is the most common blood-borne infection in America and Europe, and the most common form of liver disease, affecting nearly 5 million people in the United States, 5 million in Europe and some 200 million people worldwide. It is the leading cause of cirrhosis and liver cancer, and the number one reason for liver transplants in the United States and Europe.

About PEGINTRON

PEGINTRON is indicated for use in combination with REBETOL (ribavirin) for the treatment of chronic hepatitis C in patients 3 years of age and older with compensated liver disease.

The following
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
2. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
6. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
7. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
8. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
9. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
10. The Anatomy of Clinical Trials: Greys Season Finale Leaves Public in the Dark About the Myths and Realities
11. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... /CNW/ - Canadians face wait times of over 460 days in order ... plans, according to a new IMS Brogan report commissioned ... 16 out of 18 similar OECD countries. "It,s unimaginable ... new medicines were included in public plans, ranking Canada ... Brett Skinner , Rx&D Executive Director, Health and Economic Policy. ...
(Date:5/21/2015)... BERKELEY, Kalifornien, und KOPENHAGEN, Dänemark, 21. Mai ... , ein Weltmarktführer bei der klinischen und ... bekannt, man werde im Rahmen der weltweiten ... ca. 14.000 Liter Produktionskapazität erweitern. ... Kunden erhalten durch das innovative Einweg Bioreactor ...
(Date:5/21/2015)... -- Townsend Design announced the North America ... shell single-upright osteoarthritis (OA) knee brace. This off-the-shelf or ... reducing load on the side of the knee that ... product in other countries will begin in July. ... rigid frame and quick release buckles which make application ...
Breaking Medicine Technology:Canadians lagging well behind similar countries on access to new medicines: report 2Canadians lagging well behind similar countries on access to new medicines: report 3CMC Biologics erweitert GMP-Produktionskapazität in Europa 2CMC Biologics erweitert GMP-Produktionskapazität in Europa 3Townsend Announces Launch Of New Osteoarthritis Knee Brace 2
... -- A Pebble Beach golf tournament pays off big ... researchers took home the top prize: a $150,000 contribution from ... MS (BAMS) organization. The money will fund important studies on ... Texas Health Science Center at Houston . , , ...
... , BRIDGEWATER, N.J., July 6 ... today that the results of the long-term, 5-year study of ... of retinopathy in patients with type 2 diabetes, published on-line ... showed similar effects on retinopathy and overall safety in the ...
Cached Medicine Technology:Clay Walker's Band Against MS Foundation Donates $150,000 To Support Multiple Sclerosis Research 25-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH 25-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH 35-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH 45-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH 5
(Date:5/21/2015)... How do you stop head lice epidemics ... and school administrators, but a Miami Lice Removal Company, Lice ... southern Florida, is devising new ways to stop the spread. ... you, the first step is education and prevention. Despite the ... and how they spread are still widely misunderstood. Many continue ...
(Date:5/21/2015)... 2015 Amercanex today announced that ... first fully electronic marketplace for industrial hemp and ... marketplace in which wholesale and retail distributors of ... inventories on a fully disclosed and transparent environment. ... through a unique blend of cutting-edge infrastructure, tools, ...
(Date:5/21/2015)... 2015 Neogenis Labs , a world ... has been named to the 2015 Austin A-List by the ... South by Southwest Interactive. , The A-List companies , ... 275 nominations, were officially revealed and named to the annual ... at ACL-Live. The 12 honorees for 2015 were named in ...
(Date:5/21/2015)... ME (PRWEB) May 21, 2015 Drews Dental ... is partnering with St. Mary’s d’Youville Pavilion to provide dental ... , Geriatric oral health can be challenging for the individual ... that Dr. Drews will address include:, , ... elderly population takes and can contribute to increased cavities. , ...
(Date:5/21/2015)... Pa (PRWEB) May 21, 2015 New ... Risk of Childhood Autism , Exposure to fine particulate ... of a child’s life may be associated with an ... (ASD), a condition that affects one in 68 children, ... of Public Health investigation of children in southwestern ...
Breaking Medicine News(10 mins):Health News:Local Lice Removal Company Partners with Schools to Combat Head Lice in the Classroom as Increase in Number of Cases Reported in May. 2Health News:Amercanex is Revolutionizing Order and Efficiency in the Hemp Industry 2Health News:Neogenis® Labs Named to 2015 Austin A-List Most Promising Startups 2Health News:Neogenis® Labs Named to 2015 Austin A-List Most Promising Startups 3Health News:Peter J. Drews, DDS Provides Dental Support Services in Partnership with St. Mary’s d’Youville Pavilion 2Health News:New Research Finds Fine Particulate Air Pollution Associated with Increased Risk of Childhood Autism 2Health News:New Research Finds Fine Particulate Air Pollution Associated with Increased Risk of Childhood Autism 3Health News:New Research Finds Fine Particulate Air Pollution Associated with Increased Risk of Childhood Autism 4
... , MONDAY, April 18 (HealthDay News) -- Most people with ... their ability to smell anything at all -- adjust and learn ... usually appear to place less importance on the sense of smell ... smell. The study included 470 people, half who either lacked ...
... medicine professionals from around the world will gather at ... Dental Sleep Medicine (AADSM), which will take place Saturday, ... Minn. The meeting will be held in conjunction with ... Professional Sleep Societies. The AADSM 20th Anniversary ...
... Children,s doctors in Indiana soon will partner with ... program focused on working across state lines to ... Regional Collaborative Grant program, supported by the Indiana ... between pediatric scientists across the region, including Indiana ...
... to the 24th Congress of the European College of ... on neuropsychopharmacology, brain disorders and mental health in Europe. ... September 2011 in Paris, France, and its scientific programme ... news stories and background for strong topical features. ...
... April 18 (HealthDay News) -- Rapid weight loss in the ... no effect on strength, a new study finds. U.S. ... in 16 collegiate wrestlers. Ten days before competing, the wrestlers ... then choose a desired amount of weight to lose before ...
... survival of new brain cells after brain injury, according ... Rochester Medical Center. Jason Huang, M.D., and colleagues ... injuries who had been prescribed anti-depressants were doing better ... taking such medications. Not only did their depression ease; ...
Cached Medicine News:Health News:Poor Sense of Smell Not a Big Loss for Most People: Study 2Health News:Children's doctors team up across state lines to fight disease 2Health News:24th ECNP Congress Sept. 3-7, 2011, Paris, France 2Health News:Wrestlers' Quick Weight Loss May Cause Mental Confusion 2Health News:Anti-depressants boost brain cells after injury in early studies 2Health News:Anti-depressants boost brain cells after injury in early studies 3
... Reagents provide molecular labs a more advanced ... using our MGB technology, combined with post-PCR ... able to provide molecular labs more powerful ... specific organisms or genetic mutations associated with ...
... Reagents provide molecular labs a more advanced ... using our MGB technology, combined with post-PCR ... able to provide molecular labs more powerful ... specific organisms or genetic mutations associated with ...
... molecular labs a more advanced alternative for ... MGB technology, combined with post-PCR dissociation melt ... provide molecular labs more powerful tools for ... or genetic mutations associated with disease, as ...
... is the latest and most advanced fecal ... product line. An immunochemical FOBT (iFOBT) with ... clinically proven to detect bleeding associated with ... FOBTs. Because of its superior specificity for ...
Medicine Products: